{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Not+Condition-specific&page=6",
    "query": {
      "condition": "Not Condition-specific",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 174,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Not+Condition-specific&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Not+Condition-specific&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T20:18:40.518Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03075553",
      "title": "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Hepatosplenic T-Cell Lymphoma",
        "HTLV-1 Infection",
        "NK-Cell Lymphoma, Unclassifiable",
        "Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Anaplastic Large Cell Lymphoma",
        "Recurrent Angioimmunoblastic T-cell Lymphoma",
        "Recurrent Enteropathy-Associated T-Cell Lymphoma",
        "Recurrent Mycosis Fungoides",
        "Refractory Adult T-Cell Leukemia/Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Angioimmunoblastic T-cell Lymphoma",
        "Refractory Enteropathy-Associated T-Cell Lymphoma",
        "Refractory Mycosis Fungoides",
        "Refractory Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-05-17",
      "completion_date": "2019-05-29",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03075553"
    },
    {
      "nct_id": "NCT07468916",
      "title": "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Chronic Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified",
        "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Ropeginterferon Alfa-2B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2026-09-29",
      "completion_date": "2032-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07468916"
    },
    {
      "nct_id": "NCT00910559",
      "title": "Phenotypic and Genetic Factors in Autism Spectrum Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 1500,
      "start_date": "2008-07",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910559"
    },
    {
      "nct_id": "NCT01295502",
      "title": "Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Stage IB Cervical Cancer AJCC v6 and v7",
        "Stage IIA Cervical Cancer AJCC v7",
        "Stage IIB Cervical Cancer AJCC v6 and v7",
        "Stage IIIA Cervical Cancer AJCC v6 and v7",
        "Stage IIIB Cervical Cancer AJCC v6 and v7",
        "Stage IVA Cervical Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Internal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2011-04-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 14,
      "location_summary": "Orange, California • Hartford, Connecticut • New Britain, Connecticut + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01295502"
    },
    {
      "nct_id": "NCT01570972",
      "title": "Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder With Psychotic Features",
        "Major Depression With Psychotic Features",
        "Psychotic Disorder Not Otherwise Specified (NOS)"
      ],
      "interventions": [
        {
          "name": "Group Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Multifamily Group Psychoeducation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 103,
      "start_date": "2010-02",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570972"
    },
    {
      "nct_id": "NCT01403402",
      "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency",
        "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)",
        "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)",
        "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)",
        "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)",
        "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))",
        "Alpha-Dystroglycanopathy (Fukuyama CMD)",
        "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))",
        "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))",
        "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))",
        "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))",
        "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))",
        "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))",
        "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))",
        "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)",
        "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))",
        "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))",
        "Choline Kinase B Receptor - CHKB",
        "Collagen VI Related Disorders",
        "Collagen XII Related Disorders",
        "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)",
        "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)",
        "Congenital Muscular Dystrophy With Joint Hyperlaxity",
        "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1",
        "Emery-Dreifuss Muscular Dystrophy",
        "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement",
        "LMNA Related Disorders",
        "Merosin Deficient CMD (Full or Partial)",
        "Nesprin Related MD (SYNE1)",
        "SELENON Related Disorders (Previously Known as SEPN1)",
        "SELENON Related Myopathy (Aka SEPN1)",
        "Telethonin CMD",
        "Congenital Myasthenic Syndrome",
        "Limb-Girdle Muscular Dystrophy",
        "LGMDD01 - DNAJB6 (Formerly LGMD1D)",
        "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)",
        "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)",
        "LGMDR08 - TRIM Related (Formerly LGMD2H)",
        "LGMDR09 - FKRP Related (Formerly LGMD2I)",
        "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)",
        "LGMDR11 - POMT1 Related (Formerly LGMD2K)",
        "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)",
        "LGMDR14 - POMT2 Related (Formerly LGMD2N)",
        "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)",
        "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)",
        "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)",
        "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)",
        "LGMDR19 - GMPPB Related (Formerly LGMD2T)",
        "LGMDR20 - ISPD Related (Formerly LGMD2U)",
        "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)",
        "LGMDR23 - LAMA2 Related",
        "LGMDR24 - POMGnT2 Related"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cure CMD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4000,
      "start_date": "2009-09",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2021-08-09",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Lakewood, California",
      "locations": [
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01403402"
    },
    {
      "nct_id": "NCT07365306",
      "title": "Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent Primary Mediastinal Large B-Cell Lymphoma",
        "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2026-07-27",
      "completion_date": "2029-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Newnan, Georgia • Zion, Illinois",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07365306"
    },
    {
      "nct_id": "NCT06806033",
      "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-05",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 33,
      "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06806033"
    },
    {
      "nct_id": "NCT01443715",
      "title": "A Stepped Care Model of Adolescent Depression Treatment in Primary Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Dysthymia"
      ],
      "interventions": [
        {
          "name": "Stepped Care IPT-A (SCIPT-A)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as Usual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "13 Years to 20 Years"
      },
      "enrollment_count": 48,
      "start_date": "2011-09",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-09-04",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443715"
    },
    {
      "nct_id": "NCT07293403",
      "title": "Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Helper T-Cell Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-08-03",
      "completion_date": "2028-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-19T20:18:40.518Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07293403"
    }
  ]
}